What You Should Know:
- Boston Scientific Corporation (NYSE: BSX) announced a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK) for approximately $1.16 billion ($27.50 per share). Silk Road Medical is a leading innovator in minimally invasive stroke prevention technologies for patients with carotid artery disease.
- The acquisition strengthens Boston Scientific's position in the vascular medicine field, offering physicians a broader range of solutions for
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Athos Therapeutics Taps Vultr Cloud GPU to Power AI Drug Discovery Engine
What You Should Know:
- Vultr, the world’s largest, privately-held cloud computing platform, today announced that Athos Therapeutics, Inc. (“Athos”), a clinical-stage biotechnology company, has chosen Vultr Cloud GPU to run its AI model training, tuning, and inference.
- Powered by NVIDIA HGX H100 systems and running on Dell
Read More
Mika Health, AstraZeneca, and Daiichi Sankyo Partner on UNITE Program
What You Should Know:
- Mika Health, a leading developer of digital therapeutics for cancer patients, announced a collaborative initiative called "UNITE" alongside pharmaceutical giants AstraZeneca and Daiichi Sankyo.
- The strategic initiative signifies a commitment to cross-industry collaboration to enhance the lives of cancer patients and is expected to pave the way for AI-powered solutions in other disease areas.
Mika Health: A Proven Digital Therapeutic Platform
Mika
Read More
Medidata Launches New AI Solution to Modernize the Data Experience in Clinical Trials
What You Should Know:
- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced the launch of Medidata Clinical Data Studio, a unified experience that unlocks the true power of clinical research data.
- This groundbreaking technology gives stakeholders greater control over the quality of data and the ability to deliver safer trials to patients
Read More
Closing the Cell Therapy Access Gap with Closed Manufacturing Systems
Cell and gene therapies have the potential to revolutionize medicine. These groundbreaking treatments use living cells to target and treat disease, and they will have a profound impact on the treatment of cancer, autoimmune diseases, and beyond. However, while scientific advancements in this field are accelerating quickly, manufacturing these treatments has remained costly and slow.
The access gap between patients eligible for cell therapy and those able to receive treatment is overwhelming.
Read More
Foresite Capital Closes $900M Fund Targeting Precision Medicine & Innovation
What You Should Know:
- Foresite Capital, a San Francisco, CA-based healthcare and life sciences investment firm, announced today the successful closing of its sixth fund with a significant $900M in capital commitments. This new fund fuels Foresite's mission to invest in groundbreaking technologies across the healthcare spectrum.
- Fund VI attracted a diverse group of limited partners, including university endowments, charitable foundations, medical institutions, pension funds,
Read More
AlidaBio Secures $7.5M to Optimize Epitranscriptomic Research
What You Should Know:
- Alida Biosciences (AlidaBio), an innovator in epigenomic research tools, proudly announces the successful completion of a $7.5 million Series A funding round. This funding, led by Genoa Ventures with participation from FusionX Ventures and Vertical Venture Partners, is complemented by two ongoing SBIR grants totaling $4 million from The National Human Genome Research Institute
Read More
Komodo Health Unveils Integrated Patient Insurance Dataset for Life Sciences
What You Should Know:
- Komodo Health, a provider of real-world healthcare data and analytics, today announced the launch of Komodo Patient Insurance™ (KPI).
- The new offering delivers the most comprehensive view of patient insurance status available, encompassing over 200 million de-identified U.S. patient lives.
KPI: Unprecedented Depth and Accuracy
KPI surpasses traditional solutions by providing in-depth insights into a patient's pharmacy and medical insurance
Read More
Verily Launches AI-Powered Chronic Care Solution, Lightpath
What You Should Know:
- Verily, Alphabet's precision health subsidiary, today announced Lightpath, a next-generation chronic care solution designed to address the evolving needs of health plans and their members.
- The initial offering, Lightpath Metabolic, focuses on empowering individuals with cardiometabolic conditions to achieve and maintain their health goals. Open enrollment is targeted for early 2026.
Building on Success with Onduo
Lightpath Metabolic leverages the
Read More
Blood Test for Alzheimer’s on the Horizon: ALZpath Licenses pTau217 Antibody to Roche
What You Should Know:
- ALZpath, a leader in Alzheimer's disease diagnostics, announced a licensing agreement with Roche for their innovative pTau217 antibody. This paves the way for a blood test to diagnose Alzheimer's disease using Roche's widely used Elecsys® platform.
- The Roche pTau217 test has already received Breakthrough Device designation from the FDA and will be commercialized as part of a collaboration between Roche and Eli Lilly.
pTau217: A Game Changer in
Read More
